Search clinical trials for: MenACYW Conjugate vaccine

Total 10666 results

Sanofi Pasteur, a Sanofi Company

Recruiting

Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers

Healthy Volunteers | Meningococcal Immunisation

Czechia, Denmark, Finland, Germany, Poland, Romania
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Healthy Volunteers | Meningococcal Infection | Meningococcal Immunisation

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy

Healthy Volunteers | Meningococcal Immunisation

Argentina
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (MEQ00064)

Healthy Volunteers | Meningococcal Immunisation

South Africa, India
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Meningococcal Infections

Czechia, Finland, Italy, Poland, Romania, Spain, Sweden
Sanofi Pasteur, a Sanofi Company

Completed

Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam

Healthy Volunteers | Meningococcal Infection

Vietnam
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers

Healthy Volunteers | Meningococcal Immunisation

Spain, Finland, Germany, Hungary
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa (MET55)

Healthy Volunteers (Meningococcal Infection)

India, South Africa
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine in Older Adults Who Received a Primary Vaccination (3 or More Years Earlier) in Study MET49

Meningococcal Infection (Healthy Volunteers)

Puerto Rico, United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers (MET41)

Healthy Volunteers (Meningococcal Infection)

Puerto Rico, United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom (MET52)

Healthy Volunteers (Meningococcal Infection)

United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents

Healthy Volunteers | Meningococcal Immunisation

Spain, Hungary, Italy, Singapore
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Meningococcal Immunisation

United States, Puerto Rico
Sanofi

Completed

Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age

Meningococcal Immunisation (Healthy Volunteers)

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

Meningococcal Immunisation (Healthy Volunteers)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers

Meningococcal Immunisation (Healthy Volunteers)

Denmark, Finland, Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) in Older Adults in Turkey and Lebanon (MEQ00063)

Healthy Volunteers (Meningococcal Infection)

Lebanon, Turkey
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children

Meningococcal Infections

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers

Meningitis, Meningococcal

Korea, Republic of, Mexico, Russian Federation, Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland, Germany, Hungary, Spain
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis | Invasive Meningococcal Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Serum Institute of India Pvt. Ltd.
PATH

Completed

Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds

Meningitis, Meningococcal

Mali
Serum Institute of India Pvt. Ltd.
PATH

Completed

Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)

Meningococcal Meningitis

Gambia, Mali
Sinovac Life Sciences Co., Ltd.

Not yet recruiting

Phase I Clinical Trial of PCV24 in Adults

Pneumococcal Infectious Disease

China
Massachusetts General Hospital
International Centre for Diarrhoeal Disease Research, Bangladesh

Not yet recruiting

Correlates of Protection for Cholera (CoP)

Cholera
Sanofi Pasteur, a Sanofi Company

Recruiting

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (CORAL)

RSV Immunization

United States, Puerto Rico
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Recruiting

Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants

Healthy Volunteers

China
Germans Trias i Pujol Hospital

Not yet recruiting

Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants (LYMPHODEP)

Depression | Inflammation | Immunity | Antidepressants

Spain
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

Not yet recruiting

A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

Meningococcal Meningitis

China
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

B Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage
VA Sierra Nevada Health Care System
Merck Sharp & Dohme LLC

Not yet recruiting

Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans

Immunosuppression | Pneumococcal Vaccines
CanSino Biologics Inc.

Not yet recruiting

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

Meningococcal Meningitis
GlaxoSmithKline
Kwame Nkrumah University of Science and Technology; European & Developing Countries... and other collaborators

Recruiting

A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants

Salmonella Infections

Ghana
Leiden University Medical Center

Recruiting

Fine Needle aSpiration of Lymph nodEs to Study vAccine-induced Immunity (SEA)

Vaccine-Preventable Diseases

Netherlands
Sinovac Research and Development Co., Ltd.

Recruiting

A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Pneumococcal Infectious Disease

China
Pfizer

Recruiting

A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults

Pneumococcal Disease

United States
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013) (STRIDE-13)

Pneumococcal Infection

France, United States, Japan, Canada, Turkey, Finland, Spain, Poland, Sweden, Chile, Colombia, Israel, Thailand
Geisinger Clinic

Recruiting

Pneumonia Vaccine Education Intervention Study (PVI)

Pneumonia, Pneumococcal | Vaccine

United States
CanSino Biologics Inc.

Recruiting

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

Meningococcal Meningitis

Indonesia
State University of New York at Buffalo
National Institute on Aging (NIA)

Recruiting

The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses

Aging

United States
CanSino Biologics Inc.

Recruiting

A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)

Pertussis | Tetanus | Diphtheria

China
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

Recruiting

A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People

Pneumococcal Disease

China

3

Subscribe